The James Buchanan Brady Urological Institute
 
 
 

Dr. Kenneth Pienta LABORATORY

Clinical Trials

Dr. Pienta will see patients with high risk localized prostate cancer and advanced prostate cancer at the  Sidney Kimmel Comprehensive Cancer Center and the Brady Urological Institute at Johns Hopkins Hospital.

http://www.hopkinsmedicine.org/kimmel_cancer_center/types_cancer/prostate_cancer.html

http://www.clinicaltrials.gov


Current clinical trials include:

E2809
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 – Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy E2809

J0647
Psychopharmacology of psilocybin in cancer patients

J08107
Phase I safety study of Clostridium novyi-NT spores in patients with treatment-refractory solid tumor malignancies

J08113
A phase 1, Open-label, Multicenter, multidose, Dose-escalation Study of BMS-936558/MDX-1106 in Subjects with Selected Advance or Recurrent Malignancies

J08135
A Study of the Safety, Tolerability, and Pharmacokinetics of MORAb 004, a Humanized Monoclonal Antibody, in Subjects with Solid Tumors

J0859
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate

J0874
A Phase I study of the mTOR inhibitor Temsirolimus in combination with the HDAC inhibitor Vorinostat in patients with metastatic prostate cancer .

J09121
A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men with Castration Resistant Prostate Cancer

J0915
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects with Advanced Solid Tumors.

J0937
Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy

J1048
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects with Advanced Prostate Cancer.

J1057
Phase 1 Biodistribution and Pharmacokinetic Study of 18F-DCFBC PSMA based PET in Patients with Advanced Prostate Cancer

J1066
A phase I/IIa study of safety and efficacy of Alpharadin® with docetaxel in patients with bone metastases from castration-resistant prostate cancer

J11151
A Phase 3, randomized, double-blind, controlled trial of cabozantinib (XL184) vs. mitoxantrone plus prednisone in men with previously treated symptomatic castration resistant prostate cancer

J1128
A Phase II Trial of STA-9090 in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC) Pretreated with Docetaxel Based Chemotherapy

J1137
An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors

J1146
Efficacy and Safety of oral Kanglaite (KLTc) Gelcap in Men with Prostate Cancer: Randomized, Dose-Ranging Study of the Effects of KLTc Gelcap (3 or 6 capsules four times/day) on Prostate Specific Antigen (PSA) Doubling Time Among Men with Rising PSA Levels after Definitive Local Therapy for Prostate Cancer

J1156
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen.

J1161
Phase I/II study of safety and efficacy of Muscadine Plus (MPX) in men with prostate cancer: A randomized, double-blind, placebo-controlled study of the effects of two doses of MPX capsule on rising prostate-specific antigen in men following initial therapy for prostate cancer

J1191
Evaluation of PSMA-based PET as an imaging biomarker of primary prostate cancer

J1192
A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer

J1207
Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol and daily genistein (G-2535) versus placebo in men with early stage prostate cancer undergoing prostatectomy

J12103
A Randomized Gene Fusion Stratified Phase 2 Trial Of Abiraterone With Or Without ABT 888 For Patients With Metastatic Castration-Resistant Prostate Cancer (NCI# 9012)

J1253
A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination with BMS-936558 (Anti-PD-1) in Subjects with Advanced or Metastatic Solid Tumors

J1265
A neoadjuvant immunologic study of androgen deprivation therapy combined with a GM-CSFâ??secreting allogeneic prostate cancer vaccine and low-dose cyclophosphamide in men with high-risk localized prostate cancer undergoing radical prostatectomy

J1298
A Phase II Study of Bipolar Androgen-based Therapy for Men with Androgen Ablation Naïve Recurrent Prostate Cancer





© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287